BioCentury
ARTICLE | Company News

EC approves Puma's Nerlynx as adjuvant for breast cancer

September 4, 2018 6:04 PM UTC

The European Commission approved Nerlynx neratinib from Puma Biotechnology Inc. (NASDAQ:PBYI) for extended adjuvant treatment of adults with early hormone receptor-positive, HER2-overexpressed/amplified breast cancer within one year of completion of prior adjuvant Herceptin trastuzumab-based therapy. The company said it is the first anti-HER2 therapy approved in the EU for the indication.

Puma told BioCentury it plans to launch Nerlynx in the EU next half, but has not yet decided on a price...